The MELimmune score—prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy—a multicentre, retrospective cohort study
Using easily accessible variables from daily practice, the MELimmune prognostic score for patients with advanced melanoma treated with anti-PD-1 monotherapy holds potential to be used in clinical practice and prospectively validated in clinical trials.
Authors
- Diogo Martins-Branco (ORCID: https://orcid.org/0000-0002-7214-4818)
- P. Semedo (ORCID: https://orcid.org/0000-0002-8984-6832)
- Soraia Lobo-Martins (ORCID: https://orcid.org/0000-0001-5847-7192)
- I. Vendrell (ORCID: https://orcid.org/0000-0002-1667-5526)
- Luís Costa (ORCID: https://orcid.org/0000-0002-4782-7318)
- António M. Monteiro (ORCID: https://orcid.org/0000-0003-4467-1722)
- Cecilia Melo Alvim
- André Mansinho
- E Gouveia
- Rita Sousa (ORCID: https://orcid.org/0000-0002-9147-7896)
- M. J. Passos
Institutions
- Lisbon School of Design (PT)
- Instituto de Telecomunicações (PT)
- Hospital de Santa Maria (PT)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1016/j.iotech.2025.101043
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00